Join the Gout group to help and get support from people like you.
Gout News
Risk for Benign Prostatic Hyperplasia Increased for Patients With Gout
WEDNESDAY, Jan. 31, 2024 – Patients with gout, especially those younger than 60 years, have an increased risk for benign prostatic hyperplasia (BPH), according to a study published online Dec. 26 in...
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 – Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland...
Body Mass Index Affects Risk for Rheumatic Disease
FRIDAY, Aug. 4, 2023 – Higher body mass index (BMI) increases the risk for rheumatic disease and is a stronger risk factor for psoriatic arthropathy and gout in women, according to a study recently...
SGLT2i Use Linked to Reduced Risk for Flare in Adults With Gout, T2D
MONDAY, July 24, 2023 – For patients with gout and type 2 diabetes, sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for recurrent gout flares and gout-primary...
FDA Approves Krystexxa (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to Krystexxa with methotrexate compared to Krystexxa alone Trial data showed...
FDA Approves Gloperba (colchicine) for Prophylaxis of Adult Gout Flares
WOBURN, Mass.--(BUSINESS WIRE)--February 26, 2019 ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today...
FDA Medwatch Alert: FDA Adds Boxed Warning for Increased Risk of Death with Gout Medicine Uloric (febuxostat)
This is an update to the FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric) issued on November...
FDA Medwatch Alert: Febuxostat (Brand Name Uloric): Drug Safety Communication - FDA to Evaluate Increased Risk of Heart-related Death
ISSUE: FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called...
FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2017-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced Duzallo was approved by the U.S. Food and Drug Administration (FDA) as a once-daily...
FDA Approves Zurampic (lesinurad) to Treat High Blood Uric Acid Levels Associated with Gout
December 22, 2015 – The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in...
FDA Approves Krystexxa (pegloticase) for Gout
ROCKVILLE, Md., Sept. 14, 2010--The U.S. Food and Drug Administration today approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot...
FDA Approves Colcrys (colchicine, USP) for Prevention of Gout Flares
New Colchicine Formulation Significantly Reduces Side Effects, Maintains Full Efficacy; Now Indicated for Both Prophylaxis and Treatment of Gout Flares PHILADELPHIA, Oct. 19 /PRNewswire/ – URL...
Ask a question
To post your own question to this support group, sign in or create an account.